Thursday 24 November
EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics (ESUP)
*From the latest novelties to guidelines and protocols*

14.30 – 14.40 Welcome and introduction
Chairs: Urologist - Alberto Briganti, Milan (IT)
   Pathologist - Rodolfo Montironi, Ancona (IT)
   Urologist - James N'Dow, Aberdeen (GB)
   Urologist - Hein Van Poppel, Leuven (BE)

14.40 – 15.10 Latest novelties on the WHO morphological classifications of genitourinary cancers
Pathologist - Jonathan I. Epstein, Baltimore (US)

15.10 – 15.40 The 8th edition of the TNM staging (AJCC and UICC) of the genitourinary tumors: Implications from January 2017 and beyond
Pathologist - Mahul Amin, Los Angeles (US)

15.40 – 17.30 Round Table: From morphology to personalised medicine in genitourinary cancers

Kidney cancer
15.40 – 15.55 Update on molecular pathology with clinical implications
Pathologist - Holger Moch, Zurich (CH)

15.55 – 16.10 How to translate advances in molecular pathology into clinical practice?
Urologist - Börje Ljungberg, Umea (SE)

Prostate cancer
16.10 – 16.25 Update on molecular pathology with clinical implications
Pathologist - Cristina Magi-Galluzzi, Cleveland (US)

16.25 – 16.40 How to translate advances in molecular pathology into clinical practice?
Urologist - Nicolas Mottet, Saint-Étienne (FR)

Urothelial carcinoma
16.40 – 16.55 Update on molecular pathology with clinical implications
Pathologist - Arndt Hartmann, Erlangen (DE)

16.55 – 17.10 How to translate advances in molecular pathology into clinical practice?
TBC

17.10 – 17.30 Discussion

17.30 Close
**Friday 25 November**

08.15 – 08.30  **Welcome and Introduction**
- Medical oncologist  Thomas Powles (ESMO)
- Radiation oncologist  Peter Hoskin (ESTRO)
- Urologist  Hein Van Poppel (EAU)
- Radiologist  Raymond Oyen (ESUP)
- Pathologist  Rodolfo Montironi (ESUP)

08.30 – 10.45  **Session 1: How to use combination therapies in prostate cancer**
- **Locally advanced and high risk prostate cancer**
  - How to optimize the use of adjuvant radiation therapy after radical prostatectomy: Integrating clinical and genomic features
    - Urologist  Robert Jeffrey Karnes, Rochester (US)
  - What is the role of adjuvant systemic approaches after curative treatment?
    - Medical oncologist  Karim Fizazi, Villejuif (FR)
  - What is the best multi-modal approach for node positive disease?
    - Urologist  Karim Touijer, New York (US)
  - Salvage radiotherapy for locally recurrent disease: When and how?
    - Radiation oncologist  Gert De Meerleer, Ghent (BE)

09.30 – 09.45  Discussion

09.45 – 10.00  **Metastatic prostate cancer**
- Oligo vs polymetastatic prostate cancer: Distinct tumor entities?
  - Urologist  Anders Bjartell, Malmö (SE)
- When to use chemotherapy in hormone sensitive prostate cancer
  - Radiation oncologist  Nicholas James, Birmingham (GB)
- Combined or sequential systemic treatment for castration resistant disease?
  - Medical oncologist  Christopher Sweeney, Boston (US)

10.30 – 10.45  Discussion

10.45 – 11.15  **Coffee break and poster viewing**

11.15 – 13.00  **Session 2: Focus on uro-genital cancer variants**
- Chairs:  Pathologist – Eva Compérat, Paris (FR)
  - Urologist  Karim Touijer, New York (US)
  - Medical oncologist  Manuela Schmidinger, Vienna (AT)
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>11.15 – 11.45</strong></td>
<td>Prostate cancer</td>
<td>Variants of prostate cancer: The pathologist’s point of view</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pathologist – Rodolfo Montironi, Ancona (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate cancer variants in the setting of mCRPCa and their clinical implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urologist – Christopher Evans, Sacramento US</td>
</tr>
<tr>
<td><strong>11.45 – 12.15</strong></td>
<td>Renal cell carcinoma</td>
<td>Variants of renal cell carcinoma: The pathologist’s point of view</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pathologist – Guido Martignoni, Verona (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Variants of renal cell carcinoma: Clinical implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical oncologist – Gabriel Malouf, Paris (FR)</td>
</tr>
<tr>
<td><strong>12.15 – 13.00</strong></td>
<td>Bladder cancer</td>
<td>Variants of bladder cancer: The pathologist’s point of view</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pathologist – Antonio Lopez-Beltran, Lisbon (PT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical implications of bladder cancer variants: The medical oncologist view</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical oncologist – Maria De Santis, Coventry (GB)</td>
</tr>
<tr>
<td><strong>12.45 – 13.00</strong></td>
<td>Discussion</td>
<td>Discussion</td>
</tr>
<tr>
<td><strong>13.00 – 14.15</strong></td>
<td>Lunch break, poster viewing &amp; industry session</td>
<td>Lunch break, poster viewing &amp; industry session</td>
</tr>
<tr>
<td><strong>14.15 – 14.30</strong></td>
<td>When science meets the clinics: Genomic profiling in primary prostate cancer</td>
<td>TBC</td>
</tr>
<tr>
<td><strong>14.30 – 14.45</strong></td>
<td>Best of Journals: Radiotherapy</td>
<td>Chairs: Radiation oncologist – Bradley Pieters, Amsterdam (NL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiation oncologist – Pirus Ghadjar, Berlin (DE)</td>
</tr>
<tr>
<td><strong>14.45 – 17.45</strong></td>
<td>Session 3: Recurrent prostate cancer</td>
<td>Chairs: Radiation oncologist – Alberto Bossi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oncologist – Nicholas James, Birmingham (GB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urologist – Henk van der Poel, Amsterdam (NL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The genomic evolution of metastatic prostate cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genetist – Francesca Demichelis, Trento (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>How to use imaging for the detection of clinical progression:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The role of Multiparametric MRI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiologist – Valeria Panebianco, Zurich (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The role of PET/CT: Which tracer for which patient?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nuclear medicine physician – Stefano Fanti, Bologna (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evaluation of biopsies from sites of prostate cancer recurrence: A new standard?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urological researcher – Theo van der Kwast, Toronto (CA)</td>
</tr>
</tbody>
</table>
15.45 – 16.15  *Coffee break and poster viewing*

Imaging guided approaches for prostate cancer recurrences:

16.15 – 16.30  When is surgery the best choice?
Urologist – Steven Joniau, Leuven (BE)

16.30 – 16.45  The role of ablative radiotherapy: When and how
Radiation oncologist – Barbara Jereczek-Fossa, Milan (IT)

16.45 – 17.00  The role of focal therapy in the treatment of cancer recurrence
Urologist – Rafael Sanchez Salas, Paris (FR)

17.00 – 17.15  What is the value of imaging guided approaches in the era of early chemotherapy?
The medical oncologist’s point of view
Medical oncologist – Cora Sternberg, Rome (IT)

17.15 – 17.45  Discussion

17.45 – 18.45  *Industry session*
**Saturday 26 November**

**09.00 – 10.45**  
**Session 4: Kidney cancer: From diagnosis to progression**  
**Clinical case presentation with multidisciplinary discussion**  
**Chairs:** Pathologist – Antonio Lopez-Beltran, Lisbon (PT)  
Medical oncologist – Laurence Albignes, Villejuif (FR)  
Urologist – Axel Bex, Amsterdam (NL)

09.00 – 09.15  
**A case of 3.5 cm tumor**  
Urologist - Tobias Klatte, Vienna (AT)

09.15 – 09.30  
**The role of surveillance**  
Urologist - Phillip Pierorazio, Baltimore (US)

09.30 – 09.45  
**Partial nephrectomy: Whenever possible?**  
Urologist - Hein Van Poppel, Leuven (BE)

09.45 – 10.00  
**The role of morphology and molecular pathology**  
TBC

10.00 – 10.15  
**Follow up in kidney cancer**  
Urologist – Antonio Alcaraz, Barcelona (ES)

10.15 – 10.30  
**Metastatic disease**  
Medical oncologist - Thomas Powles, London (GB)

10.30 – 10.45  
**Discussion**

**10.45 – 11.15**  
**Coffee break and poster viewing**

**11.15 – 11.55**  
**Oral presentations of the 6 best abstracts (40 min, 6 minutes each)**  
**Chairs:** Medical oncologist - Andrea Necchi, Milan (IT)  
Medical oncologist - Manfred Wirth, Dresden (DE)  
Pathologist – Holger Moch, Zurich (CH) – declined

11.55 – 12.10  
**Lecture: The role of micro-environment in GU cancers**  
Chair: TBC  
Speaker: Biochemist – Gabri Van der Pluijm, Leiden (NL)

12.10 – 13.00  
**A focus on consequences of pelvic radiotherapy**  
**Chairs:** Radiation oncologist - Peter Hoskin, Northwood (GB)  
Urologist - George Thalmann, Berne (CH)

12.10 – 12.30  
**Pelvic radiation disease: From pathophysiology to therapy**  
Radiation oncologist - Michael Pinkawa, Aachen (DE)

12.30 – 12.40  
**The risk of secondary cancers: An under-reported clinical scenario?**  
Radiation oncologist - Cesare Cozzarini, Milan (IT)

12.40 - 12.50  
**Immune effects of pelvic radiotherapy**  
TBC

12.50 – 13.00  
**Discussion**
13.00 - 14.15  Lunch break, poster viewing and industry session

14.15 - 14.30  Update on adjuvant therapies in high risk kidney cancer. Results from phase 3 trials and future perspectives
Moderator: Urologist - Hein Van Poppel, Leuven (BE)
Speaker: Urologist - Axel Bex, Amsterdam (NL)

14.30 – 14.40  Announcement 3 best unmoderated posters (3x 2 min slide presentation)
Chairs:  Urologist - Alberto Briganti, Milan (IT)
        Urologist - Sabine Brookman-May, Munich (DE)

14.40 – 15.00  The role of Progenitor cells and organoids in the translational research of prostate cancer
Chair: Medical oncologist - Susanne Osanto, Leiden (NL)
Speaker: Scientist - Marianna Kruithof de Julio, Berne (CH)

15.00 - 15.15  Best of journals: Surgery
Chairs:  Urologist - Francesco Montorsi, Milan (IT)
        Urologist - Jochen Walz, Marseille (FR)

15.15 - 16.40  Session 5: High grade bladder Cancer: From diagnosis to progression
Clinical case presentation with multidisciplinary discussion (Case presentation T1 high grade by YAU)
Chairs:  Radiation oncologist - Piet Ost, Ghent (BE)
        Medical oncologist - Cora Sternberg, Rome (IT)
        Urologist - George Thalmann, Berne (CH)

15.15 - 15.25  Case presentation
Urologist - Evanguelos Xylinas, Paris (FR)

15.25 - 15.40  Pathology: Are all T1 high grade created equal?
Pathologist - Eva Compérat, Paris (FR)

15.40 - 15.55  How to minimize the side effects of radical cystectomy
Urologist – Jens Bedke, Tübingen (DE)

15.55 - 16.10  How to optimize patient selection for neoadjuvant chemotherapy
Urologist- Colin Dinney, Houston (US)

16.10 - 16.25  Adjuvant chemotherapy
Medical oncologist - Guru Sonpavde, Birmingham (US)

16.25 – 16.40  Immunotherapy in advanced urothelial carcinoma
Oncologist - Yohann Loriot, Villejuif (FR)

16.40 – 17.00  Coffee break and poster viewing

17.00 - 17.45  Session 6: Sports and lifestyle in uro-oncology
Chairs:  Urologist - Sabine Brookman-May, Munich (DE)
        Urologist - Bertrand Tombal, Brussels (BE)
17.00 – 17.15  Role of physical activity, sports and lifestyle in oncology – does it impact cancer incidence, oncological outcome and quality of life?
Urologist - Derek Rosario, Sheffield (GB)

17.15 - 17.30  Physiopathological impact on lifestyle on prostate health, inflammation and carcinogenesis
Urologist - Maarten Albersen, Leuven (BE)

17.30 – 17.45  Discussion

17.45 - 18.45  Industry session
Sunday 27 November

09.15 – 09.25 Announcement 3 best unmoderated posters (3x 2 min slide presentation)
Chairs: Medical oncologist - Jan Oldenburg, Oslo (NO)
Urologist - Jochen Walz, Marseille (FR)

09.25 – 09.40 Best of journals: Medical oncology
Chairs: Medical oncologist - Maria De Santis, Coventry (GB)
Medical oncologist - Jan Oldenburg, Oslo (NO)

09.40 – 11.00 Session 7: Improving active surveillance protocols in prostate cancer
Chairs: Urologist – Chris Bangma, Rotterdam (NL)
Urologist - Francesco Montorsi, Milan (IT)
Radiologist - Olivier Rouvière, Lyon (FR)

09.40 – 09.55 What is new in active surveillance?: Summary of the 2016 ESO meeting
Urologist - Peter Carroll, San Francisco (US)

09.55 - 10.10 Role of MRI in active surveillance: Strengths and limitations
Urologist - Caroline Moore, London (GB)

10.10 - 10.25 Pathology and genomics for active surveillance
Pathologist - Sara Falzarano, Cleveland (US)

10.25 - 10.40 Is active surveillance justifiable in 3+4 cancers (prognostic grade group 2)?
Urologist - Laurence Klotz, Toronto (CA)

10.40 - 11.00 Discussion

No break; ongoing coffee

11.00 - 11.20 Personalized medicine and health economics: How can expensive personalized medicine finally be profitable to health economics
Chair: Medical oncologist - Manuela Schmidinger, Vienna (AT)
Speaker: TBC

11.20 – 11.30 EU joint action on cancer control – improving prostate cancer diagnosis and care
Speaker: researcher in health services - Tit Albreht, Ljubljana (SI)

11.30 - 12.20 Take home messages
11.30 - 11.40 Radiologist Raymond Oyen, Leuven (BE)
11.40 - 11.50 Urologist Alberto Briganti, Milan (IT)
11.50 - 12.00 Medical oncologist Susanne Osanto, Leiden (NL)
12.00 - 12.10 Radiation oncologist Barbara Jereczek-Fossa, Milan (IT)
12.10 - 12.20 Pathologist Rodolfo Montironi, Ancona (IT)

12.20 - 12.30 Closing remarks
Medical oncologist Manuela Schmidinger (ESMO)
Radiation oncologist Peter Hoskin (ESTRO)
Urologist Hein Van Poppel (EAU)